ERBB2 and gastric cancer: Zolbetuximab (Vyloy), an anti-CLDN18.2 monoclonal antibody (mAb), was recently approved by the U.S. FDA for use in combination with chemotherapy in patients with HER2-negative, CLDN18.2-positive advanced GC/GEJC [7].